NetraMark Holdings 관리

관리 기준 확인 2/4

NetraMark Holdings CEO는 George Achilleos, Feb2022 에 임명되었습니다 의 임기는 2.75 년입니다. 총 연간 보상은 CA$ 265.00K, 90.6% 로 구성됩니다. 90.6% 급여 및 9.4% 보너스(회사 주식 및 옵션 포함). 는 € 430.03K 가치에 해당하는 회사 주식의 1.68% 직접 소유합니다. 430.03K. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 2.4 년입니다.

주요 정보

George Achilleos

최고 경영자

CA$265.0k

총 보상

CEO 급여 비율	90.6%
CEO 임기	2.8yrs
CEO 소유권	1.7%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	2.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

George Achilleos 의 보수는 NetraMark Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CA$11m
Mar 31 2024	n/a	n/a	-CA$12m
Dec 31 2023	n/a	n/a	-CA$13m
Sep 30 2023	CA$265k	CA$240k	-CA$14m
Jun 30 2023	n/a	n/a	-CA$13m
Mar 31 2023	n/a	n/a	-CA$12m
Dec 31 2022	n/a	n/a	-CA$13m
Sep 30 2022	CA$220k	CA$220k	-CA$13m
Jun 30 2022	n/a	n/a	-CA$9m
Mar 31 2022	n/a	n/a	-CA$10m
Dec 31 2021	n/a	n/a	-CA$8m
Sep 30 2021	CA$32k	CA$32k	-CA$5m

보상 대 시장: George 의 총 보상 ($USD 189.72K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 474.67K ).

보상과 수익: 회사가 수익성이 없는 동안 George 의 보상이 증가했습니다.

CEO

George Achilleos

2.8yrs

테뉴어

CA$265,000

보상

Mr. George Achilleos serves as Chief Executive Officer of NetraMark Holdings Inc. (formerly known as Nurosene Health Inc.) from February 17, 2022 and serves as its Director since March 28, 2024 and was its...

리더십 팀

이름	위치	테뉴어	보상	소유권
George Achilleos	CEO & Director	2.8yrs	CA$265.00k	1.68% € 430.0k
Josh Spiegel	President	2yrs	CA$403.86k	3.9% € 995.3k
Daniel Gallucci	Founder	3.9yrs	CA$32.00k	데이터 없음
Joseph Geraci	Founder	3.1yrs	CA$200.00k	6.14% € 1.6m
Swapan Kakumanu	Chief Financial Officer	2.3yrs	CA$78.00k	데이터 없음
Jaime Hackett	Vice President of Marketing	1.8yrs	데이터 없음	데이터 없음
Luca Pani	Chief Innovation & Regulatory Officer and Chief Medical Advisor	3.4yrs	데이터 없음	1.42% € 362.7k
Kaveh Kavoosi	Head of Progressive Medicine	no data	데이터 없음	데이터 없음
Larry Alphs	Chief Medical Officer & Member of Advisory Board	less than a year	데이터 없음	데이터 없음
Mark Smithyes	President of NetraMark	3yrs	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: PF0 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
George Achilleos	CEO & Director	less than a year	CA$265.00k	1.68% € 430.0k
Daniel Gallucci	Founder	3.7yrs	CA$32.00k	데이터 없음
Joseph Geraci	Founder	2.4yrs	CA$200.00k	6.14% € 1.6m
Larry Alphs	Chief Medical Officer & Member of Advisory Board	1.7yrs	데이터 없음	데이터 없음
Chuck McBride	Member of Advisory Board	no data	데이터 없음	데이터 없음
Kevin Taylor	Independent Chairman of the Board	3yrs	데이터 없음	0.34% € 87.5k
William Travis	Member of Advisory Board	no data	데이터 없음	데이터 없음
Andrew Parks	Independent Director	3.7yrs	데이터 없음	0.78% € 199.1k
Peter Carlisle	Member of Advisory Board	no data	데이터 없음	데이터 없음
Amal Wolfe	Member of Advisory Board	no data	데이터 없음	데이터 없음
Dean Sebastian	Member of Advisory Board	no data	데이터 없음	데이터 없음
Dhananja Jayalath	Member of Advisory Board	2.3yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

경험이 풍부한 이사회: PF0 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

NetraMark Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

NetraMark Holdings Inc. Announces Board Changes

NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board

NetraMark Holdings Inc. Announces Management Changes

NetraMark Holdings Inc. Appoints Dr. Maryanne Rizk to Its Strategic Advisory Board

Nurosene Health Inc., Annual General Meeting, Mar 23, 2023

Recent updates

Less than half of directors are independent

NetraMark Holdings Inc. Announces Board Changes

NetraMark Holdings Inc. Expands Product Offerings to Enhance Clinical Trial Outcomes and Improve Market Access Strategy

New major risk - Market cap size

Third quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.037 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.03 loss in 2Q 2023)

Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations

NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.045 loss in 1Q 2023)

NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering

New major risk - Financial position

NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates

NetraMark Holdings Inc. Announces Management Changes

New major risk - Shareholder dilution

NetraMark Holdings Inc. announced that it has received CAD 2 million in funding

NetraMark Holdings Inc. announced that it expects to receive CAD 1.5 million in funding

New major risk - Financial position

New major risk - Market cap size

NetraMark Holdings Inc. Appoints Dr. Maryanne Rizk to Its Strategic Advisory Board

NetraMark Holdings Inc. announced that it has received CAD 0.74235 million in funding

NetraMark Holdings Inc. announced that it expects to receive CAD 0.5 million in funding

Netramark, to Launch Clinical Trial De-Risking Technology That Integrates Chatgpt

Nurosene Health Inc., Annual General Meeting, Mar 23, 2023

Less than half of directors are independent

Nurosene Health Inc. announced that it has received CAD 0.80225 million in funding

Nurosene Health Inc. announced that it has received CAD 0.07475 million in funding

Nurosene Health Inc. announced that it has received CAD 0.7275 million in funding

Nurosene Health Inc. Appoints Neurosurgeon Douglas James Cook as Chief Medical Officer

Nurosene Health Inc. Appoints Dhananja Jayalath to Its Advisory Board

Nurosene Health Inc. Appoints Dr. Luca Pani as Chief Innovation and Regulatory Officer

Nurosene Health Inc. Appoints Swapan Kakumanu as Chief Financial Officer

Nurosene Health Inc. Announces Resignation of Blake Sing as Chief Financial Officer

Nurosene Health Inc. announced that it has received CAD 0.595 million in funding

Less than half of directors are independent

Nurosene Health Inc. Appoints Gino DeMichele to its Board of Directors

Nurosene Health Inc. Advances Brain Health with the Launch of its Science-First Nuro App

Nurosene Announces Executive Changes

Nurosene Health Inc. Introduces NetraPlacebo

Nurosene Health Inc. Announces Resignation of Kirstine Stewart as Director

Nurosene Health Inc., Annual General Meeting, Apr 01, 2022

Chairman of the Board recently bought €84k worth of stock

Nurosene Health Inc. Releases Preliminary Findings That Support the Innovation of Anti-Aging Therapeutics

High number of new and inexperienced directors

Nurosene Health Inc. (CNSX:MEND) entered into a non-binding term sheet to acquire NetraMark Incorporated for CAD 15 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간